Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axys Pharmaceuticals

Division of Quest Diagnostics Inc.
www.celera.com

Latest From Axys Pharmaceuticals

Terra Infirma: Pharma Dealmaking 2001

With Big Pharma still trying to figure out how to create productive businesses from their mega-mergers, most of the year's high-value M&A saw biotechs buying late-stage or marketed products. But these biotechs are also, with the risk of development failure ever clearer, actively in-licensing and acquiring products and product-creating technologies in order to diversify what are often single-product portfolios. Unlike many Big Pharmas, these companies have been willing to improve existing chemical entities, often exploiting drug delivery and other pharmaceutical sciences. Meanwhile, large companies focused on late-stage in-licensing, in part because they couldn't afford acquisitions--given the valuation disparities between large companies and small ones with valuable late-stage products. Nonetheless, while more affordable than acquisitions, the high price of these deals has transferred the majority of the regulatory and commercial risk to the licensee. As for the early-stage side of the biotech industry: platform companies have not been able to sell their discovery technologies at anything like the prices they expected; as a result, many of them have merged in an effort to create product-focused discovery operations.
BioPharmaceutical Strategy

The Asthma Challenge

Armed with a better understanding of the bad actors in the misguided immune response that causes allergies, companies hope to develop long-lasting treatments for asthma.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Khepri
  • Arris Pharmaceutical
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Quest Diagnostics Inc.
  • Senior Management
  • Paul Hastings, Pres. & CEO
    William J Newell, SVP, Corp. & Bus. Dev.
    Michael C Venuti, PhD, SVP, R&D
  • Contact Info
  • Axys Pharmaceuticals
    Phone: (650) 829-1000
    180 Kimball Way
    S. San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register